1. Home
  2. PRE vs RCEL Comparison

PRE vs RCEL Comparison

Compare PRE & RCEL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Prenetics Global Limited

PRE

Prenetics Global Limited

N/A

Current Price

$23.60

Market Cap

301.5M

Sector

Industrials

ML Signal

N/A

Logo Avita Medical Inc.

RCEL

Avita Medical Inc.

N/A

Current Price

$9.88

Market Cap

306.5M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
PRE
RCEL
Founded
2014
N/A
Country
Hong Kong
United States
Employees
N/A
N/A
Industry
Biotechnology: Laboratory Analytical Instruments
Medical/Dental Instruments
Sector
Industrials
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
301.5M
306.5M
IPO Year
2021
2018

Fundamental Metrics

Financial Performance
Metric
PRE
RCEL
Price
$23.60
$9.88
Analyst Decision
Strong Buy
Buy
Analyst Count
2
5
Target Price
$30.50
$7.88
AVG Volume (30 Days)
278.6K
360.8K
Earning Date
06-11-2026
05-14-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
27.20
EPS
N/A
N/A
Revenue
N/A
$71,610,000.00
Revenue This Year
$108.69
$17.17
Revenue Next Year
$58.68
$49.82
P/E Ratio
N/A
N/A
Revenue Growth
N/A
11.45
52 Week Low
$9.29
$3.22
52 Week High
$27.24
$11.39

Technical Indicators

Market Signals
Indicator
PRE
RCEL
Relative Strength Index (RSI) 54.71 59.18
Support Level $17.49 $3.64
Resistance Level $27.24 $10.77
Average True Range (ATR) 1.69 0.55
MACD -0.07 -0.19
Stochastic Oscillator 63.62 15.02

Price Performance

Historical Comparison
PRE
RCEL

About PRE Prenetics Global Limited

Prenetics Global Ltd is a consumer health and wellness company offering nutrition and longevity products through its flagship brand, IM8. It offers science-backed daily nutrition and longevity products distributed directly to consumers across multiple countries. The company's products are developed with scientific input and are subject to third-party quality certifications.

About RCEL Avita Medical Inc.

Avita is largely a single product company. Its RECELL system is an innovative burn treatment device which creates Spray-on Skin from a small skin sample within 30 minutes, thus avoiding or reducing the need for skin grafts. It's approved for the treatment of adult and paediatric patients in the US and an expanded indication for soft-tissue reconstruction. It is currently used in most of the 140 US burn centers. Despite having product approval in Australia, Canada, and China, Avita is not actively marketing in those territories and focussing instead on the US region, although international sales, particularly in Japan, are growing. Avita is domiciled, and has its primary listing, in the US.

Share on Social Networks: